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Abstract
Introduction: Limited evidence suggests that serum alkaline phosphatase activity may decrease after cardiac
surgery in adults and children. The importance of this finding is not known. Recent studies, however, have
identified a potential role for alkaline phosphatase as modulator of inflammation in multiple settings, including
during adult cardiopulmonary bypass. We sought to describe the change in alkaline phosphatase activity after
cardiothoracic surgery in infants and to assess for a correlation with intensity and duration of post-operative
support, markers of inflammation, and short-term clinical outcomes.
Methods: Sub-analysis of a prospective observational study on the kinetics of procalcitonin in 70 infants (≤90 days
old) undergoing cardiothoracic surgery. Subjects were grouped based on the use of cardiopulmonary bypass and
delayed sternal closure. Alkaline phosphatase, procalcitonin, and C-reactive protein (CRP) levels were obtained pre-
operation and on post-operative day 1. Mean change in alkaline phosphatase activity was determined in each
surgical group. Generalized linear modeling and logistic regression were employed to assess for associations
between post-operative alkaline phosphatase activity and post-operative support, inflammation, and short term
outcomes. Primary endpoints were vasoactive-inotropic score at 24 hours and length of intubation. Secondary
endpoints included procalcitonin/CRP levels on post-operative day 1, length of hospital stay, and cardiac arrest or
death.
Results: Mean decrease in alkaline phosphatase was 30 U/L (p = 0.01) in the non-bypass group, 114 U/L
(p<0.0001) in the bypass group, and 94 U/L (p<0.0001) in the delayed sternal closure group. On multivariate
analysis, each 10 U/L decrease in alkaline phosphatase activity on post-operative day 1 was independently
associated with an increase in vasoactive-inotropic score by 0.7 (p<0.0001), intubation time by 6% (p<0.05), hospital
stay by 5% (p<0.05), and procalcitonin by 14% (P<0.01), with a trend towards increased odds of cardiac arrest or
death (OR 1.3; p = 0.06). Post-operative alkaline phosphatase activity was not associated with CRP (p = 0.7).
Conclusions: Alkaline phosphatase activity decreases after cardiothoracic surgery in infants. Low post-operative
alkaline phosphatase activity is independently associated with increased procalcitonin, increased vasoactive/
inotropic support, prolonged intubation time, and prolonged hospital stay. Alkaline phosphatase may serve as a
biomarker and potential modulator of post-operative support and inflammation following cardiothoracic surgery in
infants.
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Introduction
Alkaline phosphatase (AP) is an endogenous metalloen-
zyme with four distinct isoenzymes (tissue non-specific,
intestinal, placental, and germ cell). Post-translational
modifications of the non-specific tissue-form result in a
total of six distinct liver and bone isoforms [1-3]. AP is
uniformly present in serum where the primary isoforms
originate from liver and bone, and to a smaller extent
from the intestine.
Recently, AP has garnered renewed research interest as
a component of the host defense against inflammation,
in part due to its ability to neutralize endotoxin [4-9].
Exogenously administered AP produces beneficial effects
on inflammation in models of ulcerative colitis [7,10],
necrotizing enterocolitis [11], and sepsis [6,12-14].
Systemic inflammation is common after cardiac surgery,
and profound or prolonged inflammation can adversely
affect surgical outcomes [15]. Cardiac surgery and cardio-
pulmonary bypass (CPB) trigger the systemic inflamma-
tory response through various mechanisms including
surgical trauma, hypothermia, exposure to foreign materi-
als and blood products, ischemia reperfusion, and splanch-
nic hypoperfusion with intestinal mucosal damage and
endotoxin leak [15-17]. AP may have a protective role
against systemic inflammation in patients after CPB [8,9].
Two prior studies, one in children undergoing repair of
congenital heart disease and one in adults undergoing
coronary artery bypass grafting, described significant
decreases in AP activity following cardiac surgery with
CPB [18,19]. Neither study was able to identify an etiol-
ogy for the decrease, nor did the authors explore the clin-
ical implications of this decrease. We sought to better
describe the decrease in AP activity after cardiothoracic
surgery in infants and to assess whether CPB was a
necessary mediator. We further hypothesized that lower
post-operative AP activity would correlate with increased
inflammation, increased post-operative support, and pro-
longed post-operative care.
Materials and methods
Patients were enrolled as part of a prospective, observa-
tional study examining the post-operative kinetics of the
inflammatory marker procalcitonin (PCT) in infants ≤ 90
days of age, undergoing cardiothoracic surgery. The pro-
tocol was approved by the Colorado Multiple Institution
Review Board. Exclusion criteria were estimated gesta-
tional age < 34 weeks or weight < 1,200grams at the time
of surgery. The study was performed in a single tertiary
care center with dedicated pediatric cardiovascular oper-
ating rooms and cardiac intensive care unit (CICU).
Study size was determined by power analysis from the
procalcitonin study. Investigation of AP was performed
as a sub-analysis of the PCT trial. Patient enrollment
occurred between July 2009 and September 2010. Surro-
gate informed consent was obtained from parents or
legal guardians in all cases. All enrolled patients com-
pleted the study protocol.
Baseline demographic and surgical information collected
on all patients included gender, ethnicity, gestational age
at delivery, age and weight at the time of surgery, anatomic
diagnosis, surgical procedure, Aristotle comprehensive
complexity score [20,21], use of pre-operative steroids,
CPB time, aortic cross-clamp time, and deep hypothermic
circulatory arrest (DHCA) time. By protocol, all patients
underwent pre-operative assessment of PCT, C-reactive
protein (CRP), and liver function tests (LFTs), including
total AP activity while under anesthesia immediately prior
to the opening incision. AP activity was determined by the
commercially available VITROS ALKP Slide method using
the VITROS Chemistry Products Calibrator Kit 3 (Ortho
Clinical Diagnostics, Rochester, New York, USA). Rate of
change of p-nitrophenyl phosphate to p-nitrophenol by
AP was monitored by reflectance spectrophotometry and
the rate of change in reflection was converted to enzyme
activity.
CPB was performed using a neonatal circuit consisting
of a roller head pump (Terumo System 1, Ann Arbor, MI,
USA) and a Terumo FX05 oxygenator with a blood prime.
The prime routinely underwent hemofiltration using a
Sorin DHFO.6 hemoconcentrator (Sorin Group USA, Inc.,
Arvada, CO, USA) with a polyethersulfone membrane
prior to initiating bypass, allowing for partial filtration of
molecules up to 65,000 Daltons. Anticoagulation was
achieved prior to CPB by administering 400 units/Kg of
heparin systemically to the patient. Initial target flow rate
was approximately 200 ml/Kg/minute. Cardioplegia was
accomplished using del Nido formula cardioplegia solution
at an initial dose of 30 ml/Kg and subsequent dosing was
considered after 45 to 60 minutes of aortic cross-clamp
time. Conventional ultrafiltration was utilized throughout
CPB. After CPB, modified ultrafiltration was employed to
remove inflammatory mediators and increase hematocrit.
Patients were separated into three groups based on the
following operative characteristics: 1) delayed sternal clo-
sure (DSC), 2) CPB without DSC, and 3) no CPB or DSC.
Group assignment primarily determined the blood draw
schedule for PCT and CRP. The decision to perform DSC
was made by the attending surgeon as a precaution in
patients with poor function, significant myocardial edema,
or other concerns for low cardiac output. Invasive arterial
and central venous pressure monitoring were performed
in all cases. Inotropic and vasoactive medications were
initiated at the discretion of the surgical team. Ongoing
titration was directed by the intensivist and did not follow
a pre-established protocol. Vasoactive-inotropic score
(VIS) was calculated as per Gaies et al. [22] at 24, 48, and
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72 hours after admission to the CICU. PCT and CRP
levels were drawn on post-operative day 1 (POD1) in all
patients. Patients in groups one and two also had LFTs
drawn between 0400 and 0600 on POD1. Additional
laboratory testing was performed as directed by the
intensivist.
The primary study objective was to describe the
changes in AP activity from pre-operation to POD1. Sec-
ondary goals included the assessment of associations
between post-operative AP activity and post-operative
support, inflammation, and short term outcomes.
Primary clinical endpoints determined a priori were VIS
at 24 hours after CICU admission (VIS24) and length of
intubation in hours. Secondary endpoints included VIS at
48 and 72 hours after CICU admission (VIS48, VIS72),
length of CICU and hospital stay, PCT on POD1, and
CRP on POD1. Given the low expected mortality, a com-
bined dichotomous poor outcome variable as previously
described was utilized as a secondary outcome [22]. Poor
outcome was defined as the occurrence of any one of the
following events or interventions: cardiac arrest requiring
chest compressions, death within 30 days or at any point
prior to discharge, renal replacement therapy, or
mechanical circulatory support.
Baseline characteristics were expressed as means with
SD for normally distributed data and medians with
quartiles for nonparametric data. Comparisons of base-
line variables between groups were performed using the
chi-square test for categorical data and two-sample
t-test or Mann-Whitney U-test for continuous variables.
Pre-operative and POD1 AP activity were compared
within each surgical group utilizing the paired t-test.
Outcome distributions were examined prior to model-
ing. Highly skewed data were log transformed unless they
contained negative values or excessive zeros, in which
case the outcomes were dichotomized as upper 25th per-
centile vs. lower 75th percentile (VIS48 and 72). General
linear modeling was employed to model outcomes that
were normally distributed with either original data or fol-
lowing log transformation. Logistic regression was
applied to model the dichotomized data. Potential covari-
ates included surgical group, age, Aristotle comprehen-
sive score, weight at surgery, bypass time, cross-clamp
time, DHCA time, and the presence of single ventricle
physiology. Spearman correlation testing between out-
comes and candidate variables was first performed to
identify potential covariates. Candidate variables with a
P-value from correlation testing that was less than 0.1
were then selected for multiple regression. Further corre-
lation testing was performed among identified covariates
to identify potential confounders. Backwards stepwise
regression was used to identify significant covariates with
a P-value cutoff of 0.1. Surgical group was strongly asso-
ciated with all outcomes and was kept in all models to
control for clinical differences. Pre-operative AP activity
and PCT/CRP levels were also kept in all appropriate
models. All other potential covariates assessed did not
contribute substantially to model fit and were excluded.
R-square/adjusted R-square were used to evaluate per-
cent variability due to AP in general linear models, while
the receiver operator characteristic (ROC) curve and the
area under the curve (AUC) were generated to evaluate
the sensitivity and specificity in predicting dichotomized
outcomes. Model results are reported as change per 10
U/L of AP for normally distributed outcomes, percentage
change per 10 U/L of AP for nonparametric outcomes,
and change in odds ratio per 10 U/L of AP for dichoto-
mized outcomes. P-values smaller than 0.05 were consid-
ered statistically significant.
Results
Enrollment details are presented in Figure 1. A total of 70
patients were enrolled and completed the study. Of the 70
patients enrolled, 56 underwent CPB, of which 26 required
DSC. One additional patient did not undergo CPB but
required DSC due to shunt malfunction and immediate
reoperation for shunt revision. One patient was found to
have an inaccurate date of birth in the medical record, was
older than inclusion criteria permitted, and was excluded
from all subsequent analyses.
Demographic and baseline surgical data are shown in
Table 1. Overall, the DSC and non-bypass patients were
younger than the general CBP patients, and the DSC
patients weighed significantly less at the time of operation.
The DSC group had higher Aristotle scores, a higher pre-
valence of single ventricle physiology, and greater use of
pre-operative steroids. Median bypass time and DHCA
time were also longer in the DSC group, although aortic
cross-clamp time was comparable.
Median pre-operative and POD1 AP activity are shown
in Table 2. Pre-operative AP activity was significantly
higher in the CPB group than in either the non-bypass or
DSC groups. AP activity was assessed on POD1 in 63 of
69 patients. Two patients (one in the non-bypass group
and one in the DSC group) died on POD0. Three addi-
tional patients in the non-bypass group and one patient in
the DSC group did not have an AP drawn on POD1, at
the discretion of the clinical team. AP activity on POD1
dropped in 62 of the 63 remaining patients compared to
their pre-op activity. Median AP activity on POD1 was sig-
nificantly lower in the DSC group than in the non-bypass
or CPB groups. Mean changes in AP activity for patients
in each surgical group are demonstrated in Table 3. All
three groups showed a statistically significant mean
decrease in patients’ AP activity with a greater mean
decrease in the CPB and DSC groups than in the non-
bypass group. Changes in AP activity were not correlated
with changes in albumin (r = 0.18, P not significant), total
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protein (r = 0.12, P not significant), or AST (r = -0.04, P
not significant), but showed a moderate inverse correlation
with ALT (r = -0.54, P < 0.0001).
Post-operative support and short-term outcomes for
each group are shown in Table 4. Overall, the DSC group
required significantly more post-operative support as
demonstrated by higher median VIS24, 48, and 72, and
longer median intubation time, CICU stay, and hospital
stay. The DSC group also exhibited a greater incidence of
combined poor outcome. Spearman correlation testing
was used to assess univariate associations between AP on
POD 1 and post-operative support. AP activity on POD1
demonstrated a statistically significant moderate inverse
correlation with VIS at 24 (r = -0.69; P < 0.0001), 48 (r =
-0.65; P <0.0001), and 72 hours (r = -0.61; P < 0.0001), as
well as length of intubation (r = -0.54; P < 0.0001), length
of CICU stay (r = -0.52; P < 0.0001), and length of hospi-
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Figure 1 Patient enrollment flow chart.







P-value No CPB vs.
CPB




Male 8 (62%) 16 (55%) 18 (67%) ns ns ns
Ethnicity ns ns ns
White 9 (69%) 18 (62%) 15 (56%)
Hispanic 4 (31%) 10 (34%) 11 (40%)
Other 0 (0%) 1 (4%) 1 (4%)
Age, days 11 (3, 14) 49 (9, 67) 5 (4, 19) < 0.0001 ns < 0.005
Weight, Kg 2.9 (2.5, 3.6) 3.4 (3.1, 4) 3.1 (2.8, 3.4) ns ns <0.01
Aristotle score 8 (7, 8) 10 (7, 11) 12 (10, 15) < 0.05 <0.0001 < 0.005




n/a n/a < 0.05
Cross-clamp time,
minutes
n/a 86 (61, 113) 76 (56, 93) n/a n/a ns
DHCA time, minutes n/a 0 (0, 0) 22 (0, 35) n/a n/a < 0.01
Single ventricle
physiology
3 (23%) 2 (7%) 12 (44%) ns ns < 0.005
Pre-operative steroids 1 (8%) 12 (41%) 23 (85%) < 0.05 < 0.0001 < 0.005
Unless otherwise specified, categorical data are expressed as n (%) and continuous data are expressed as median (25th, 75th percentile). CPB, cardiopulmonary
bypass; DSC, delayed sternal closure; DHCA, deep hypothermic circulatory arrest; ns, not significant; n/a, not applicable.
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relationship of AP activity to VIS24, length of intubation,
and length of hospital stay across the entire cohort are
shown in Figure 2.
We next performed general linear modeling to assess
the association between AP and outcomes while control-
ling for potential confounding variables (Table 5). Con-
trolling for surgical group and pre-operative AP activity,
each 10 U/L decrease in AP on POD1 was independently
associated with an increase in VIS24 of 0.7 (P < 0.0001),
a 6% increase in intubation time (P < 0.05), and a 5%
increase in length of hospital stay (P < 0.05). Similarly,
length of CICU stay increased by 4% for each 10 U/L
decrease in AP on POD1, but this increase was not statis-
tically significant. Two additional outcomes (VIS48 and
VIS72) were assessed by multiple logistic regression due
to the presence of excessive zero values. Cutoffs for
VIS48 and VIS72 were 12 and 10 respectively. Each
10 U/L decrease in AP was independently associated with
increased odds of high VIS48 and VIS72 (P < 0.005).
Statistics of model fit are included in Table 4. Overall,
based on these models, AP activity on POD1 was respon-
sible for between 5 and 15% of the variation in post-
operative support. Additional modeling using the change
in AP activity as the independent variable showed no sig-
nificant association with post-operative support (data not
shown).
Poor outcome occurred in nine patients (five deaths
and four additional cardiac arrests). No patients required
mechanical circulatory support or renal replacement
therapy. Two deaths occurred prior to assessment of AP
activity on POD1 leaving a total of seven events for ana-
lysis. The association between poor outcome and AP
activity on POD1 was assessed using ROC analysis. The
AUC based on ROC analysis was 0.78 (95% CI 0.66 to
0.90). Of interest, all poor outcome events analyzed
occurred in patients with AP activity less than 90 U/L.
Multiple logistic regression modeling controlling for sur-
gical group and pre-operative AP activity showed a trend
towards increased odds of poor outcome for each 10 U/L
decrease in AP activity on POD1 (Table 5).
Inflammatory biomarker data are shown in Table 6.
Pre-operation, median PCT and CRP levels were normal
in all groups with the exception of a mild elevation of
median PCT in the non-bypass group. There was a mod-
erate inverse correlation between pre-op PCT and AP
activity (r = -0.47, P < 0.0001) and a weak inverse correla-
tion between CRP and AP activity (r = -0.30; P < 0.05).
The patients with the highest pre-operative PCT levels
uniformly carried a diagnosis that placed them at risk for
decreased systemic blood flow (severe left sided obstruc-
tive lesion, pulmonary atresia/intact ventricular septum,
single ventricle with complete heart block) and the
majority (eight out of ten) exhibited significant lactic
acidosis (greater than 2 mmol/L) in the pre-operative
period. On POD1, PCT and CRP levels were elevated in
all surgical groups.
We next performed multiple linear regression modeling
controlling for surgical group, pre-operative AP activity,
and pre-operative PCT/CRP levels (Table 5). Based on
these models there was no significant association between
AP activity and CRP level on POD1. We did, however,
find a strong association between PCT level and AP activ-
ity on POD1. By our model, each 10 U/L decrease in AP
activity on POD1 predicted a 14% increase in PCT level
(P < 0.01).
Discussion
The primary aim of this study was to assess the changes in
total serum AP activity around cardiothoracic surgery in
infants. Our study is the largest to date to examine serum
AP activity in any patient population undergoing cardi-
othoracic surgery. In 1974, Neutze et al. briefly described
a post-operative decrease in total serum AP activity in 15
children undergoing cardiac surgery with profound
hypothermia and limited CPB [19]. The authors did not
further explore the etiology or clinical changes associated
with decreased AP. Lum et al. followed activity in 25 adult
CPB patients and showed a 48% decrease in AP activity
relative to baseline, compared to a decrease of approxi-
mately 15% in non-cardiac surgery patients [18]. Serial AP
Table 2 Alkaline phosphatase activity, measured pre-operatively and on post-operative day 1
No CPB CPB DSC P-value No CPB vs. CPB P-value No CPB vs. DSC P-value CPB vs. DSC
AP (U/L), Pre-op 143 (128, 173) 236 (150, 302) 155 (28, 297) < 0.05 ns < 0.005
AP (U/L), POD1 112 (70, 148) 141 (77, 166) 61 (45, 78) ns < 0.05 < 0.0001
Alkakine phosphatase (AP) levels are presented as median (25th, 75th percentiles). CPB, cardiopulmonary bypass; DSC, delayed sternal closure; AP, alkaline
phosphatase; POD, post-operative day; ns, not significant.
Table 3 Mean change in alkaline phosphatase activity measured pre-operatively and on post-operative day 1
Surgical group Number Mean difference, U/L (SD) 95% CI P-value
No bypass 9 -29.9 (26.5) (- 50.3, -9.5) < 0.01
CPB 29 -114.4 (97.6) (-152.2, -76.5) < 0.0001
DSC 25 -93.8 (47.1) (-112.8, -74.7) <0.0001
CPB, cardiopulmonary bypass; DSC, delayed sternal closure; CI, confidence interval.
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activity demonstrated a nadir on POD1 with subsequent
recovery over the next 7 to 10 days.
In our population, pre-operative AP activity varied sig-
nificantly between surgical groups. Specifically, the CPB
group showed higher pre-operative activity than the
non-CPB and DSC groups. These differences were
anticipated given the older age of the CPB cohort and
the normal age variations in AP activity during infancy
[3]. However, it is possible that additional factors such
as pre-operative cardiovascular instability and inflamma-
tion could modulate pre-operative AP activity. While no
patients received enteral feeding within six hours of sur-
gery, enteral feeding status in the days prior to surgery
may also have played a role.
Despite these pre-operative differences, we found that
AP activity decreased following surgery in almost every
case. Often this drop was quite profound. DSC patients
showed the greatest relative drop in AP activity with an
average decrease > 60%. We also found that these changes
were not exclusive to infants exposed to CPB. While the
decrease was generally smaller, eight out of nine patients
in the non-CPB group exhibited a decrease in their AP
activity. The one patient who underwent DSC without
CPB exhibited a greater AP decrease of 132 U/L, suggest-
ing that large decreases in AP activity following surgery
cannot be purely ascribed to the use of CPB.
Our study was not designed to determine the etiology
of decline in AP activity following cardiothoracic surgery.
However, we are able to make three preliminary observa-
tions. First, removal of AP by the circuit during hemofil-
tration is an unlikely etiology, as AP is a large molecule
(> 65,000 Daltons) and the Sieving coefficient through a
polyethersulfone membrane is effectively zero. Second, in
contrast to the findings of Lum et al. [18], total protein
and albumin increased in our patients following surgery,
and changes in total protein and albumin did not corre-
late with changes in AP. These findings make dilution
less likely as an etiology, although albumin replacement
was not monitored in this study. Third, liver injury is also
unlikely as a mechanism, as AP activity was inversely
related to ALT, the opposite of the typical pattern in liver
congestion or injury [1].
The secondary objective of our study was to examine the
relationship between decreased AP activity to require-
ments and duration of post-operative support, and short
term clinical outcomes. In our population, lower total AP
Table 4 Post-operative support and outcomes






P-value No bypass vs.
CPB




Intubation, hours 28 (16, 48) 40 (18, 72) 117 (74,
165)
ns < 0.001 <0.0001
Length of hospital stay,
days
12 (6, 15) 10 (7, 14) 21 (13, 28) ns < 0.01 <0.0005
Length of ICU stay, days 3 (2.5, 6) 4 (3, 7) 9 (6, 15) ns < 0.05 <0.01
VIS24 0 (0, 3) 8 (3, 11) 15 (12, 20) < 0.005 < 0.0001 <0.0001
VIS48 0 (0, 0) 3 (0, 7) 13 (10, 18) < 0.05 < 0.0001 <0.0001
VIS72 0 (0, 0) 0 (0, 4) 11 (5, 15) ns < 0.001 <0.0001
Poor outcome 1 (9%) 1 (4%) 7 (26%) ns ns <0.05
Unless otherwise specified, categorical data are expressed as n (%) and continuous data are expressed as median (25th, 75th percentiles). CPB, cardiopulmonary
bypass; DSC, delayed sternal closure; ICU, intensive care unit; VIS, vasoactive-inotropic score; ns, not significant.
Figure 2 Scatter plot for alkaline phosphatase (AP) versus VIS24 (A), intubation time (B), and length of hospital stay (C).
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activity on POD1 was independently associated with
increased intensity and duration of post-operative support,
including higher vasoactive and inotropic medication
requirements, prolonged intubation time, and increased
length of hospital stay. The change in AP activity was not
as significant as the absolute activity on POD1, in predict-
ing the need for post-operative support. While the pre-
dicted change in support for each unit decrease in AP
activity is relatively small, the large differences in post-
operative AP activity make these predicted changes clini-
cally relevant. For example, comparing patients at the 25th
and 75th percentile in the CPB group (AP 77 vs. 166 U/L),
those in the 25th percentile would be expected to have an
approximate increase in VIS of 6 (equivalent to the addi-
tion of 6 mcg/kg/minute of dopamine or 0.06 mcg/kg/
minute of epinephrine), a 50% increase in intubation time,
and a 40% increase in length of hospital stay. We did note
a small trend towards increased odds of cardiac arrest or
death in patients with lower AP activity. In particular, AP
activity below 90 U/L appeared to be a sensitive predictor
of cardiac arrest or death in our population, and might
be a candidate threshold for future observational and
interventional research. However, the study size was insuf-
ficient to draw any definitive conclusions regarding post-
operative AP activity and cardiac arrest or death.
Given these associations with post-operative support
and the trend towards differences in the frequency of poor
outcomes, AP activity may have some utility as a predictor
of increased post-operative support. We did not, however,
examine its predictive strength compared to other avail-
able biomarkers (such as lactate trends) or scoring systems
(such as VIS) already proven to predict differences in out-
come. Of greater potential interest, however, is the ques-
tion of whether AP activity is simply a marker of disease
severity, or if AP has a true biologic role in modulating the
response to cardiothoracic surgery. Due to the observa-
tional design of the study, we cannot directly draw conclu-
sions about cause and effect. Recent literature, however,
has suggested that AP may be active in multiple inflamma-
tory and ischemic settings [2-7,10,12-14,16]. AP displays
various potentially beneficial actions including modulation
of nitric oxide synthase [13] and dephosphorylation of
extracellular ATP [23]. The link between AP and inflam-
mation is also a topic of active research. AP is capable of
dephosphorylating the lipid-A moiety of endotoxin, con-
verting it to a non-toxic monophosphoryl product [2-7].
AP may also target additional bacterial components such
as CpG DNA and flagellin [4]. In cardiac surgery, endo-
toxin release from the intestine is thought to be one trig-
ger for systemic inflammation, and AP may play a role in
reducing this inflammation [8]. To assess if there was a
potential link between AP and systemic inflammation in
our population, we examined the association between AP
and the two inflammatory biomarkers available for analysis
through the parent PCT study (PCT and CRP). We were
able to demonstrate that lower AP activity on POD1 was
Table 5 Multivariate modeling: change in outcome variable per 10 U/L decrease in alkaline phosphatase (AP) activity*
Outcome variable AP POD1 (95% CI) P-Value R2 AUC (95% CI)
Intubation, % change 6% (1%, 12%) < 0.05 0.47 n/a
Length of hospital stay, % change 5% (2%, 9%) < 0.05 0.35 n/a
Length of ICU stay, % change 4% (-3%, 8%) ns 0.3 n/a
VIS24, unit change 0.7 (0.4, 1.0) < 0.0001 0.70 n/a
VIS48, OR for change 1.4 (1.1, 1.7) < 0.005 n/a 0.93 (0.87, 1.0)
VIS72, OR for change 1.4 (1.2, 1.7) <0.005 n/a 0.89 (0.81, 0.97)
Poor outcome, OR for change 1.3 (1, 1.8) 0.061 n/a 0.78 (0.66, 0.90)
PCT, POD1, % change 14% (4%, 25%) < 0.01 0.26 n/a
CRP, POD1, %change -4% (-17%, 27%) ns 0.30 n/a
*change expressed as unit change for normally distributed variables, % change for log transformed variables, and odds ratio (OR) change for data with excessive
zero values (logistic regression). ICU, Intensive care unit; VIS, vasoactive-inotropic score; POD, post-operative day; PCT, procalcitonin; CRP, C-reactive protein; AUC,
area under the curve; CI, confidence interval; ns, not significant; n/a, not applicable.
Table 6 Inflammatory markers
No bypass CPB DSC P-value No bypass vs.
CPB












< 0.005 ns < 0.05
PCT, ng/ml, POD1 1.1 (0.4, 2.8) 2.4 (1.4, 9.5) 3.1 (2.0, 4.4) ns 0.05 ns
CRP, mg/dl, pre-
operation
0.7 (0.5, 1.1) 0.5 (0.1, 0.5) 0.3 (0.1, 0.5) < 0.05 < 0.01 ns
CRP, mg/dl, POD1 5.3 (2.9, 8.2) 6.1 (3.9, 8.1) 3.5 (2.0, 4.4) ns ns < 0.005
Unless otherwise specified, categorical data are expressed as n (%) and continuous data are expressed as median (25th, 75th percentile). CPB, cardiopulmonary
bypass; DSC, delayed sternal closure; PCT, procalcitonin; CRP, C-reactive protein; POD, post-operative day.
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strongly associated with increased PCT but not CRP levels.
PCT is highly activated by endotoxin [24-26], and prior
pediatric studies of cardiac arrest and CPB have shown
that elevated levels of PCT, but not CRP, are predictive of
poor outcome [24-26]. In this study AP activity was also
inversely correlated with PCT levels before the operation,
generally in the setting of poor systemic blood flow and
lactic acidosis. These data provide some initial evidence
for a possible biologic mechanism for AP in our
population.
If low AP activity decreases the protective host response
to cardiothoracic surgery, then supplementation of AP to
higher levels could potentially allow for a reduction in
post-operative support requirements. Evidence in favor of
AP as a therapeutic agent in various disease processes has
recently been established. Enteral administration of AP
has been shown to improve outcomes in rat models of
necrotizing enterocolitis and Crohn’s Disease [10,12].
Administration of Resolvin-E1 in a rat model of Crohn’s
disease increased expression of intestinal AP and reduced
disease activity, improvements which were blunted with
inhibition of intestinal AP activity [5]. Administration of
exogenous AP has also been effective in animal models of
systemic inflammation [6,14].
Several human trials have been performed using AP
supplementation. An uncontrolled trial in adults with
ulcerative colitis showed that administration of oral AP for
seven days resulted in decreased CRP levels and improved
clinical response scores [7]. Heemskerk, et al. assessed the
effects of AP on renal injury in adult patients with severe
sepsis/septic shock [13]. AP-treated patients showed an
improvement in serum creatinine and glutathione S-trans-
ferase A1-1 compared to controls, possibly due to a
demonstrated reduction in the expression of renal nitric
oxide synthase. In a follow-up study, Pickkers, et al.
showed improvement in a combined renal function out-
come as well as a reduction in systemic inflammatory mar-
kers in the AP group compared to placebo [23]. In
addition to the effects of AP on endotoxin, this group also
suggested a role for AP in the dephosphorylation of extra-
cellular ATP. Kats, et al. evaluated the effects of exogen-
ous AP on inflammation and outcomes in adult patients
undergoing coronary artery bypass grafting [8]. Given the
overall favorable clinical course, the study was underpow-
ered to assess a difference in surgical outcomes. However,
AP-treated patients did not demonstrate the post-opera-
tive rise in the inflammatory markers TNF a, IL-6, and
IL-8 seen in a portion of control patients. The authors
hypothesized that AP might play a role in preventing post-
bypass inflammation, potentially by limiting endotoxin
leak from the hypoperfused gastrointestinal tract.
In summary, our study confirms that the decrease in
AP activity seen in prior studies reliably occurs in infants
undergoing cardiothoracic surgery. Low AP activity was,
in turn, associated with the need for increased post-
operative support. Patients with low post-operative AP
activity may also have an increased risk of cardiac arrest
or death, but our study was underpowered to confirm
this association. Low post-operative AP activity was sig-
nificantly associated with elevated PCT levels, providing
limited initial evidence for a link between AP and one
pathway of systemic inflammation. Based on these
results, we believe serum AP may represent an important
mediator and potential therapeutic target following cardi-
othoracic surgery in infants.
There are several limitations to our study. First, it
represents a single center experience and generalizability
to other centers has not been established. Second, the
protocol was designed to answer questions about procal-
citonin and CRP rather than AP. The research was there-
fore restricted by the structure and sample size of the
parent study. The sample size was underpowered to
assess more rare events such as mortality, cardiac arrest,
and the need for mechanical support. Small sample size
also limited the scope of covariate assessment in our
multivariate analysis. The sub-analysis design limited the
collection of additional data of interest, such as specific
changes in isoforms, the timing of AP recovery, broader
inflammatory biomarker analysis, and endotoxin assays.
These aspects should be addressed in future studies. One
specific issue of the parent study design concerns the
protocols for assessing AP activity. No AP activity was
sampled in the very early post-operative period (0 to 6
hours), and data could have been missed on the kinetics,
etiology, and relationship to early (POD 0) deaths. POD 1
AP activity was not mandated in the non-CPB group
resulting in three patients who could not be analyzed,
and potentially limiting the conclusions that can be
drawn from this group. Also, all AP activity was assessed
at the same time point on POD1 regardless of the time of
surgery, potentially introducing an element of bias if sur-
gery performed later in the day differed substantially
from morning surgery. Finally, as mentioned previously,
this study is observational in design and cannot establish
causality. Further research is required to assess whether
modulation of AP activity in the peri-operative period
will affect post-operative support, inflammation, or
outcomes.
Conclusions
Infants undergoing cardiothoracic surgery experience a
predictable post-operative decrease in serum alkaline
phosphatase activity. This decrease is more marked in
patients undergoing CPB, but is not dependent on the use
of bypass. Low alkaline phosphatase activity on post-
operative day 1 is independently associated with increased
requirement for vasoactive/inotropic medication, pro-
longed intubation time, and prolonged hospital stay with a
Davidson et al. Critical Care 2012, 16:R160
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trend towards increased odds of cardiac arrest or death.
Decreased AP activity is associated with increased PCT
levels both before and after surgery.
Key messages
• AP functions as part of the host defense against
inflammation in part through the detoxification of
endotoxin and other bacterial products.
• Serum AP activity declines following cardiovascular
surgery in infants.
• Low AP activity following cardiothoracic surgery in
infants is independently associated with increased
vasoactive/inotropic requirements, intubation time,
and length of hospital stay.
• Low AP activity is associated with increased PCT
levels.
Abbreviations
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